The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11149 malaria professionals are enjoying the free benefits of MalariaWorld today

efficacy trials

Plasmodium falciparum histidine rich protein 2 (pfhrp2): an additional genetic marker suitable for anti-malarial drug efficacy trials

January 12, 2022 - 23:38 -- Open Access
Author(s): 
Wahib M. Atroosh, Yee-Ling Lau, Georges Snounou, Meram Azzani and Hesham M. Al-Mekhlafi
Reference: 
Malaria Journal 2022 21:2, 4 January 2022

Genotyping of the three Plasmodium falciparum polymorphic genes, msp1, msp2 and glurp, has been adopted as a standard strategy to distinguish recrudescence from new infection in drug efficacy clinical trials. However, the suitability of a particular gene is compromised in areas where its allelic variants distribution is significantly skewed, a phenomenon that might occur in isolated parasite populations or in areas of very low transmission. Moreover, observation of amplification bias has diminished the value of glurp as a marker.

The WorldWide Antimalarial Resistance Network Clinical Trials Publication Library: A Live, Open-Access Database of Plasmodium Treatment Efficacy Trials

May 21, 2020 - 06:39 -- Open Access
Author(s): 
Takata J, Sondo P, Humphreys GS, Burrow R, Maguire B, Hossain MS, Das D, Commons RJ, Price RN, Guerin PJ
Reference: 
Am J Trop Med Hyg. 2020 May 18

Parasite resistance to antimalarial drugs poses a serious threat to malaria control. The WorldWide Antimalarial Resistance Network (WWARN) aims to provide a collaborative platform to support the global malaria research effort. Here, we describe the “WWARN clinical trials publication library,” an open-access, up-to-date resource to streamline the synthesis of antimalarial safety and efficacy data.

Subscribe to RSS - efficacy trials